ABSTRACT El presente proyecto persigue dos objetivos esenciales: dotar al alumnado de herramienta... more ABSTRACT El presente proyecto persigue dos objetivos esenciales: dotar al alumnado de herramientas que le permitan mejorar su aprendizaje, potenciando su participación, y favorecer el abordaje multidisciplinar de las patologías estudiadas al poner en contacto a alumnos de diferentes grados, futuros profesionales de la salud, que podrán compartir experiencias y aportar diferentes puntos de vista a problemas comunes.
A 16 mujeres premenopausicas que van a ser sometidas a ooforectomia bilateral se les evalua antes... more A 16 mujeres premenopausicas que van a ser sometidas a ooforectomia bilateral se les evalua antes, a los 3 meses y a los 12 meses, valorando la aparicion de sintomas psicologicos, transtornos del sueno, sintomas de deficit estrogenico y manifestaciones musculoesqueleticas (especialmente STC, S. Fibromialgico y osteoporosis). A los 3 meses de la intervencion, 8 reciben THS. Tras el seguimiento se observa: una elevada perdida de masa osea en las pacientes no tratadas; las pacientes con niveles estrogenicos premonopausicos mas elevados presentaron mas sintomas vasomotores; las pacientes ooforectomizadas no tratadas presentaron mas cansancio a los 12 meses; las pacientes ooforectomizadas presentan una mayor tendencia al dolor, probablemente mediada por trastornos psicologicos, del sueno y por sintomas vasomotores; las pacientes ooforectomizadas, tratadas y no tratadas, presentan una tendencia aumentada a padecer sindrome del tunel carpiano.
Background: Janus kinase (JAK) inhibitor is a great addition to the therapeutic options for rheum... more Background: Janus kinase (JAK) inhibitor is a great addition to the therapeutic options for rheumatoid arthritis (RA). However, the the clinical efficacy and safety of tofacitinib comparing with methotrexate (MTX) was not elucidated. Objectives: We conducted a controlled randomized clinical trial in treatment naive rheumatoid arthritis (RA) patients to explore the clinical efficacy and safety of tofacitinib (TOFA) comparing with MTX. Methods: In this open-label, randomized, and controlled clinical trial, treatment naive RA patients at the status of medium or high disease activity [simplified disease activity index (SDAI)>3.3] were randomized at 1:1 ratio into TOFA and MTX groups. Patients in TOFA group received tofacitinib 5 mg twice per day and patients in MTX group received MTX 10-15 mg once per week plus betamethasone 1ml muscle injection at enrollment. The rate of disease activity improvement (defined as SDAI decreased >50% against baseline or at least 10) at week 12 was taken as primary outcome. Patients who did not achieve improvement transferred to the other group. Secondary outcomes included the rates of remission, low disease activity (LDA) and change of disease activity scores. Results: 100 patients were enrolled in the study with 49 in TOFA group and 51 in MTX group. The improvement rate was much higher in TOFA group than in MTX group [29.3% (12/41) vs 7.5% (3/40), p=0.025]. The rate of remission and low disease activity at week 4 and week 12 were comparable between the two groups. The change of
BackgroundGiant cell arteritis (GCA) is the most common form of systemic vasculitis. The standard... more BackgroundGiant cell arteritis (GCA) is the most common form of systemic vasculitis. The standard treatment to induce and maintain remission of GCA is based on the use of glucocorticoids (GC), often requiring high doses and for long periods of time. It has been associated with adverse events, sometimes severe, in up to 95% of cases (fractures, diabetes mellitus, hypertension, sepsis). In 2017, the first specific drug for this entity, tocilizumab (TCZ), an anti-IL-6 antibody, was approved. To date, there are few communications in clinical practice comparing the classical treatment scheme with the use of TCZ early.ObjectivesTo compare patients treated with the standard regimen (corticosteroid monotherapy) versus those treated early with TCZ, in terms of the dose of corticosteroid received, use of immunosuppressants, and adverse events.MethodsA retrospective observational study was carried out. Patients diagnosed with GCA in the Rheumatology section of the HGU Dr. Balmis during the period January 1, 2011, to November 1, 2021, were selected. Until 2017, patients received the standard regimen (corticosteroid monotherapy); from 2017, TCZ was associated early. Demographic data, treatment data (prednisone doses at months 1,3,6,12,18 and 24; use of immunosuppressants), and adverse events were collected. A descriptive analysis of the different variables was performed. The χ2 test or Fisher’s exact test was used for the association between qualitative variables. For quantitative variables, mean comparison was performed using the t-student test.ResultsWe obtained 73 patients (37% male and 63% female) with a mean age at diagnosis of 74.47 ± 8.4 years. All received initial corticosteroid treatment; 28 were also administered early TCZ (38.4%), the preferred route being subcutaneous (96.4%). The time between diagnosis and initiation of steroid treatment was a median of 0 days (median, IC 0-0), being 60 days for TCZ (IC 30-97). The use of immunosuppressants was higher in the glucocorticoid-only group than in the group treated with TCZ (57.8% vs. 21.4%, p=0.002). Prednisone dose was higher in the standard group at all follow-up time points (p<0.001). No differences were found in the occurrence of adverse events, except infections, which were more frequent in the standard treatment group (standard 28.9% vs TCZ 3.6%, p=0.008).ConclusionTocilizumab allows a greater and faster reduction of corticosteroids, compared to standard corticosteroid monotherapy, lower use of other immunosuppressants, and is associated with a lower frequency of infections.References[1]Palmowski A, Buttgereit F. Reducing the Toxicity of Long-Term Glucocorticoid Treatment in[2]Large Vessel Vasculitis. Curr Rheumatol Rep. 12 de octubre de 2020;22(12):85.[3]Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79(1):19-130.[4]Stone JH, Klearman M, Collinson N. Trial of tocilizumab in giant-cell arteritis. New Engl J Med 2017;377(15):1494-1495.Acknowledgements:NIL.Disclosure of InterestsPaloma Vela Casasempere Speakers bureau: ROCHE, Grant/research support from: ROCHE, Lorena Tudela: None declared, Rocio Caño-Alameda: None declared, Silvia Gomez-Sabater: None declared.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the ad... more This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
European Medical Journal Rheumatology, Jul 25, 2014
We conducted a study to determine the prevalence of extraarticular manifestations (ExRA) in a coh... more We conducted a study to determine the prevalence of extraarticular manifestations (ExRA) in a cohort of predominantly Hispanic and Asian patients with rheumatoid arthritis (RA), to identify factors associated with the development of ExRA, and to compare the prevalence of ExRA between Hispanic and Asian patients. Patients with RA followed in the outpatient rheumatology clinics of a public hospital were included if they were aged Q18 years and met the 1987 American College of Rheumatology criteria for the diagnosis of RA. We performed a cross-sectional analysis in which patients with ExRA were identified based on predefined criteria. We compared sociodemographic and clinical characteristics in patients with and without ExRA. Multivariate logistic regression was used to examine the association between sociodemographic variables, clinical characteristics, and the presence of ExRA. The prevalence of ExRA was 21.5%, and the most common manifestations were subcutaneous nodules (17.2%) and interstitial lung disease (3.6%). Hispanic patients were significantly more likely to develop ExRA than Asian patients (odds ratio, 2.53; 95% confidence interval, 1.26Y5.09). The development of ExRA was also associated with disease duration, male sex, and seropositivity for serum rheumatoid factor.
Looking for a needle in a haystack A 56-year-old man with long-standing chronic seronegative poly... more Looking for a needle in a haystack A 56-year-old man with long-standing chronic seronegative polyarthritis was first seen in our clinic. Treatment with synthetic DMARD and anti-TNF drugs was ineffective in controlling inflammation, and structural damage was obvious. A clinical exam showed prominent indurated nodules in both elbows. For an accurate diagnosis, aspiration of a nodule for microscopic examination was performed. The small sample obtained showed abundant cholesterol crystals (Figure 1a, compensated polarized light), but a careful examination allowed identifying typical acicular crystals with a strong negative birefringence characteristic of monosodium urate (Figure 1b, black arrow,-λ shows the compensator axis), confirming the diagnosis of gout. Cholesterol crystals are commonly found in chronic processes, but they are not specific (1). However, the finding of monosodium urate crystals allows the accurate diagnosis of gout. Joint, bursa, or nodule aspiration is a simple and easy procedure, and it could result in findings as interesting and useful as these.
a b s t r a c t The biological therapies based in the anti-tumor necrosis factor- (TNF) are an ef... more a b s t r a c t The biological therapies based in the anti-tumor necrosis factor- (TNF) are an effective alternative for the treatment of chronic inflammatory diseases. However, given that anti-TNF- therapy has been associated with reactivation of latent tuberculosis infection, a previous evaluation of the patients is required in order to avoid their progression to active TB in case of being infected. Tuberculin skin testing (TST) is used to diagnose tuberculosis infection but it has low specificity in patients who have received the BCG vaccine and low sensitivity in patients with altered cell-mediated immunity. In vitro assays based on the detection of interferon- (IFN) released by T cells stimulated by specific Mycobacterium tuberculosis antigens have emerged as an option for the diagnosis of tuberculosis infection. The results to date show, that they are a viable alternative to TST thanks to their higher specificity and sensitivity. Although there are some preliminary results indicating that the IFN- tests could be used alone, at the moment it seems more prudent to use them in combination with the TST, considering infection when either of them is positive.
Cochrane Database of Systematic Reviews, Sep 18, 2014
To determine the efficacy and safety of certolizumab pegol (CDP870) and if it has clinical benefi... more To determine the efficacy and safety of certolizumab pegol (CDP870) and if it has clinical benefits for people with rheumatoid arthritis (RA) who do not respond well to conventional disease-modifying anti-rheumatic drugs (DMARDs).
up studies and prospective interventional studies are required to confirm this positive associati... more up studies and prospective interventional studies are required to confirm this positive association between SUA and lung function.
up studies and prospective interventional studies are required to confirm this positive associati... more up studies and prospective interventional studies are required to confirm this positive association between SUA and lung function.
Background: Mild forms of adult hypophosphatasia may have subtle manifestations, and may go unrec... more Background: Mild forms of adult hypophosphatasia may have subtle manifestations, and may go unrecognized Objectives: To get a better knowledge of its clinical spectrum. Methods: We performed a computerized search of low total alkaline phosphatase among laboratory records. The diagnosis of hypophosphatasia was confirmed by measuring serum pyridoxal phosphate (PLP) and bone alkaline phosphatase. Carotid ultrasonography was performed in patients and controls with a MyLab 70 scanner (Esaote; Genoa, Italy), equipped with 7-12 MHz linear transducer. Results: Over a 31 month period, we identified 130 individuals with at least one determination of serum alkaline phosphatase less than 26 u/l. After reviewing the clinical records, unexplained persistently low levels were found in 42 individuals who accepted to participate in the study (10 men, 32 women). Age range was 20-77 yr (mean 51). Total alkaline phosphatase levels were positively correlated with bone alkaline phosphatase (r=0.52, p<0.001). Serum PLP was inversely correlated with bone alkaline phosphatase. Ten individuals (24%) had PLP levels above the reference range of 175 nmol/l, consistent with hypophosphatasia. In comparison with those with normal PLP levels, these individuals had higher frequency of hypertension (50 vs 12%, p=0.02). Likewise, individuals with hypophosphatasia showed a trend to have early atherosclerotic disease. Carotid ultrasound showed bilateral plaques in 4 out of 9 patients (44%), and only in 26% of the age and sex-matched controls. The intima-media thickness also tended to be increased in the patients (670±70 vs. 648±110 microns; p=0.18). Conclusions: These preliminary data suggest that individuals with adult hypophosphatasia may be at increased cardiovascular risk. The results should be confirmed in larger studies.
can be reached within a few months of pegloticase treatment. DECT allows for comprehensively asse... more can be reached within a few months of pegloticase treatment. DECT allows for comprehensively assessing tophus burden and monitoring treatment responses.
contacting SB, SC and CH. MALDI/TO-TOF analysis revealed the exchange of peptides and proteins be... more contacting SB, SC and CH. MALDI/TO-TOF analysis revealed the exchange of peptides and proteins between contacting cells including calnexin, calreticulin or CD44 antigen. Conclusions: These findings suggest that Cx43-mediated intercellular communication between cells located in the subchondral bone, synovial membrane and cartilage may contribute to the cellular signalling and homeostasis of the joint and may have protective effect in the injured tissues and hence warrants further investigation. So far, the results presented here demonstrated for the first time that SB, SC and CH are able to physically interact and directly communicate by GJ channels.
ABSTRACT El presente proyecto persigue dos objetivos esenciales: dotar al alumnado de herramienta... more ABSTRACT El presente proyecto persigue dos objetivos esenciales: dotar al alumnado de herramientas que le permitan mejorar su aprendizaje, potenciando su participación, y favorecer el abordaje multidisciplinar de las patologías estudiadas al poner en contacto a alumnos de diferentes grados, futuros profesionales de la salud, que podrán compartir experiencias y aportar diferentes puntos de vista a problemas comunes.
A 16 mujeres premenopausicas que van a ser sometidas a ooforectomia bilateral se les evalua antes... more A 16 mujeres premenopausicas que van a ser sometidas a ooforectomia bilateral se les evalua antes, a los 3 meses y a los 12 meses, valorando la aparicion de sintomas psicologicos, transtornos del sueno, sintomas de deficit estrogenico y manifestaciones musculoesqueleticas (especialmente STC, S. Fibromialgico y osteoporosis). A los 3 meses de la intervencion, 8 reciben THS. Tras el seguimiento se observa: una elevada perdida de masa osea en las pacientes no tratadas; las pacientes con niveles estrogenicos premonopausicos mas elevados presentaron mas sintomas vasomotores; las pacientes ooforectomizadas no tratadas presentaron mas cansancio a los 12 meses; las pacientes ooforectomizadas presentan una mayor tendencia al dolor, probablemente mediada por trastornos psicologicos, del sueno y por sintomas vasomotores; las pacientes ooforectomizadas, tratadas y no tratadas, presentan una tendencia aumentada a padecer sindrome del tunel carpiano.
Background: Janus kinase (JAK) inhibitor is a great addition to the therapeutic options for rheum... more Background: Janus kinase (JAK) inhibitor is a great addition to the therapeutic options for rheumatoid arthritis (RA). However, the the clinical efficacy and safety of tofacitinib comparing with methotrexate (MTX) was not elucidated. Objectives: We conducted a controlled randomized clinical trial in treatment naive rheumatoid arthritis (RA) patients to explore the clinical efficacy and safety of tofacitinib (TOFA) comparing with MTX. Methods: In this open-label, randomized, and controlled clinical trial, treatment naive RA patients at the status of medium or high disease activity [simplified disease activity index (SDAI)>3.3] were randomized at 1:1 ratio into TOFA and MTX groups. Patients in TOFA group received tofacitinib 5 mg twice per day and patients in MTX group received MTX 10-15 mg once per week plus betamethasone 1ml muscle injection at enrollment. The rate of disease activity improvement (defined as SDAI decreased >50% against baseline or at least 10) at week 12 was taken as primary outcome. Patients who did not achieve improvement transferred to the other group. Secondary outcomes included the rates of remission, low disease activity (LDA) and change of disease activity scores. Results: 100 patients were enrolled in the study with 49 in TOFA group and 51 in MTX group. The improvement rate was much higher in TOFA group than in MTX group [29.3% (12/41) vs 7.5% (3/40), p=0.025]. The rate of remission and low disease activity at week 4 and week 12 were comparable between the two groups. The change of
BackgroundGiant cell arteritis (GCA) is the most common form of systemic vasculitis. The standard... more BackgroundGiant cell arteritis (GCA) is the most common form of systemic vasculitis. The standard treatment to induce and maintain remission of GCA is based on the use of glucocorticoids (GC), often requiring high doses and for long periods of time. It has been associated with adverse events, sometimes severe, in up to 95% of cases (fractures, diabetes mellitus, hypertension, sepsis). In 2017, the first specific drug for this entity, tocilizumab (TCZ), an anti-IL-6 antibody, was approved. To date, there are few communications in clinical practice comparing the classical treatment scheme with the use of TCZ early.ObjectivesTo compare patients treated with the standard regimen (corticosteroid monotherapy) versus those treated early with TCZ, in terms of the dose of corticosteroid received, use of immunosuppressants, and adverse events.MethodsA retrospective observational study was carried out. Patients diagnosed with GCA in the Rheumatology section of the HGU Dr. Balmis during the period January 1, 2011, to November 1, 2021, were selected. Until 2017, patients received the standard regimen (corticosteroid monotherapy); from 2017, TCZ was associated early. Demographic data, treatment data (prednisone doses at months 1,3,6,12,18 and 24; use of immunosuppressants), and adverse events were collected. A descriptive analysis of the different variables was performed. The χ2 test or Fisher’s exact test was used for the association between qualitative variables. For quantitative variables, mean comparison was performed using the t-student test.ResultsWe obtained 73 patients (37% male and 63% female) with a mean age at diagnosis of 74.47 ± 8.4 years. All received initial corticosteroid treatment; 28 were also administered early TCZ (38.4%), the preferred route being subcutaneous (96.4%). The time between diagnosis and initiation of steroid treatment was a median of 0 days (median, IC 0-0), being 60 days for TCZ (IC 30-97). The use of immunosuppressants was higher in the glucocorticoid-only group than in the group treated with TCZ (57.8% vs. 21.4%, p=0.002). Prednisone dose was higher in the standard group at all follow-up time points (p&lt;0.001). No differences were found in the occurrence of adverse events, except infections, which were more frequent in the standard treatment group (standard 28.9% vs TCZ 3.6%, p=0.008).ConclusionTocilizumab allows a greater and faster reduction of corticosteroids, compared to standard corticosteroid monotherapy, lower use of other immunosuppressants, and is associated with a lower frequency of infections.References[1]Palmowski A, Buttgereit F. Reducing the Toxicity of Long-Term Glucocorticoid Treatment in[2]Large Vessel Vasculitis. Curr Rheumatol Rep. 12 de octubre de 2020;22(12):85.[3]Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79(1):19-130.[4]Stone JH, Klearman M, Collinson N. Trial of tocilizumab in giant-cell arteritis. New Engl J Med 2017;377(15):1494-1495.Acknowledgements:NIL.Disclosure of InterestsPaloma Vela Casasempere Speakers bureau: ROCHE, Grant/research support from: ROCHE, Lorena Tudela: None declared, Rocio Caño-Alameda: None declared, Silvia Gomez-Sabater: None declared.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the ad... more This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
European Medical Journal Rheumatology, Jul 25, 2014
We conducted a study to determine the prevalence of extraarticular manifestations (ExRA) in a coh... more We conducted a study to determine the prevalence of extraarticular manifestations (ExRA) in a cohort of predominantly Hispanic and Asian patients with rheumatoid arthritis (RA), to identify factors associated with the development of ExRA, and to compare the prevalence of ExRA between Hispanic and Asian patients. Patients with RA followed in the outpatient rheumatology clinics of a public hospital were included if they were aged Q18 years and met the 1987 American College of Rheumatology criteria for the diagnosis of RA. We performed a cross-sectional analysis in which patients with ExRA were identified based on predefined criteria. We compared sociodemographic and clinical characteristics in patients with and without ExRA. Multivariate logistic regression was used to examine the association between sociodemographic variables, clinical characteristics, and the presence of ExRA. The prevalence of ExRA was 21.5%, and the most common manifestations were subcutaneous nodules (17.2%) and interstitial lung disease (3.6%). Hispanic patients were significantly more likely to develop ExRA than Asian patients (odds ratio, 2.53; 95% confidence interval, 1.26Y5.09). The development of ExRA was also associated with disease duration, male sex, and seropositivity for serum rheumatoid factor.
Looking for a needle in a haystack A 56-year-old man with long-standing chronic seronegative poly... more Looking for a needle in a haystack A 56-year-old man with long-standing chronic seronegative polyarthritis was first seen in our clinic. Treatment with synthetic DMARD and anti-TNF drugs was ineffective in controlling inflammation, and structural damage was obvious. A clinical exam showed prominent indurated nodules in both elbows. For an accurate diagnosis, aspiration of a nodule for microscopic examination was performed. The small sample obtained showed abundant cholesterol crystals (Figure 1a, compensated polarized light), but a careful examination allowed identifying typical acicular crystals with a strong negative birefringence characteristic of monosodium urate (Figure 1b, black arrow,-λ shows the compensator axis), confirming the diagnosis of gout. Cholesterol crystals are commonly found in chronic processes, but they are not specific (1). However, the finding of monosodium urate crystals allows the accurate diagnosis of gout. Joint, bursa, or nodule aspiration is a simple and easy procedure, and it could result in findings as interesting and useful as these.
a b s t r a c t The biological therapies based in the anti-tumor necrosis factor- (TNF) are an ef... more a b s t r a c t The biological therapies based in the anti-tumor necrosis factor- (TNF) are an effective alternative for the treatment of chronic inflammatory diseases. However, given that anti-TNF- therapy has been associated with reactivation of latent tuberculosis infection, a previous evaluation of the patients is required in order to avoid their progression to active TB in case of being infected. Tuberculin skin testing (TST) is used to diagnose tuberculosis infection but it has low specificity in patients who have received the BCG vaccine and low sensitivity in patients with altered cell-mediated immunity. In vitro assays based on the detection of interferon- (IFN) released by T cells stimulated by specific Mycobacterium tuberculosis antigens have emerged as an option for the diagnosis of tuberculosis infection. The results to date show, that they are a viable alternative to TST thanks to their higher specificity and sensitivity. Although there are some preliminary results indicating that the IFN- tests could be used alone, at the moment it seems more prudent to use them in combination with the TST, considering infection when either of them is positive.
Cochrane Database of Systematic Reviews, Sep 18, 2014
To determine the efficacy and safety of certolizumab pegol (CDP870) and if it has clinical benefi... more To determine the efficacy and safety of certolizumab pegol (CDP870) and if it has clinical benefits for people with rheumatoid arthritis (RA) who do not respond well to conventional disease-modifying anti-rheumatic drugs (DMARDs).
up studies and prospective interventional studies are required to confirm this positive associati... more up studies and prospective interventional studies are required to confirm this positive association between SUA and lung function.
up studies and prospective interventional studies are required to confirm this positive associati... more up studies and prospective interventional studies are required to confirm this positive association between SUA and lung function.
Background: Mild forms of adult hypophosphatasia may have subtle manifestations, and may go unrec... more Background: Mild forms of adult hypophosphatasia may have subtle manifestations, and may go unrecognized Objectives: To get a better knowledge of its clinical spectrum. Methods: We performed a computerized search of low total alkaline phosphatase among laboratory records. The diagnosis of hypophosphatasia was confirmed by measuring serum pyridoxal phosphate (PLP) and bone alkaline phosphatase. Carotid ultrasonography was performed in patients and controls with a MyLab 70 scanner (Esaote; Genoa, Italy), equipped with 7-12 MHz linear transducer. Results: Over a 31 month period, we identified 130 individuals with at least one determination of serum alkaline phosphatase less than 26 u/l. After reviewing the clinical records, unexplained persistently low levels were found in 42 individuals who accepted to participate in the study (10 men, 32 women). Age range was 20-77 yr (mean 51). Total alkaline phosphatase levels were positively correlated with bone alkaline phosphatase (r=0.52, p<0.001). Serum PLP was inversely correlated with bone alkaline phosphatase. Ten individuals (24%) had PLP levels above the reference range of 175 nmol/l, consistent with hypophosphatasia. In comparison with those with normal PLP levels, these individuals had higher frequency of hypertension (50 vs 12%, p=0.02). Likewise, individuals with hypophosphatasia showed a trend to have early atherosclerotic disease. Carotid ultrasound showed bilateral plaques in 4 out of 9 patients (44%), and only in 26% of the age and sex-matched controls. The intima-media thickness also tended to be increased in the patients (670±70 vs. 648±110 microns; p=0.18). Conclusions: These preliminary data suggest that individuals with adult hypophosphatasia may be at increased cardiovascular risk. The results should be confirmed in larger studies.
can be reached within a few months of pegloticase treatment. DECT allows for comprehensively asse... more can be reached within a few months of pegloticase treatment. DECT allows for comprehensively assessing tophus burden and monitoring treatment responses.
contacting SB, SC and CH. MALDI/TO-TOF analysis revealed the exchange of peptides and proteins be... more contacting SB, SC and CH. MALDI/TO-TOF analysis revealed the exchange of peptides and proteins between contacting cells including calnexin, calreticulin or CD44 antigen. Conclusions: These findings suggest that Cx43-mediated intercellular communication between cells located in the subchondral bone, synovial membrane and cartilage may contribute to the cellular signalling and homeostasis of the joint and may have protective effect in the injured tissues and hence warrants further investigation. So far, the results presented here demonstrated for the first time that SB, SC and CH are able to physically interact and directly communicate by GJ channels.
Uploads
Papers by Paloma Vela